|1.||Cooper, Garth J S: 12 articles (09/2015 - 09/2004)|
|2.||Phillips, Anthony R J: 6 articles (09/2015 - 09/2004)|
|3.||Lu, Jun: 6 articles (01/2013 - 02/2007)|
|4.||Brewer, George J: 5 articles (08/2009 - 12/2003)|
|5.||Gamble, Gregory D: 4 articles (01/2013 - 09/2004)|
|6.||Poppitt, Sally D: 4 articles (06/2010 - 09/2004)|
|7.||Endoh, Daiji: 4 articles (10/2007 - 11/2004)|
|8.||Hayashi, Masanobu: 4 articles (10/2007 - 11/2004)|
|9.||Okui, Toyo: 4 articles (10/2007 - 11/2004)|
|10.||Zhang, Shaoping: 3 articles (09/2015 - 09/2009)|
|1.||Hepatolenticular Degeneration (Wilson's Disease)
07/09/2011 - "Trientine (TETA dihydrochloride) has been used since the mid-1980s as a second-line treatment for Wilson's disease, and our recent clinical studies have reinforced the impression that it is likely to be safe for long-term use in patients with diabetes and related metabolic disorders. "
04/23/1999 - "In this study, trientine and ascorbate, known to have a beneficial effect in an animal model of Wilson disease, were administered to transgenic mice overexpressing a mutated human SOD1 (G93A). "
09/01/1993 - "[A study of trientine therapy in Wilson's disease with neurological symptoms]."
02/01/2016 - "Wilson's disease with cognitive impairment and without extrapyramidal signs: improvement of neuropsychological performance and reduction of MRI abnormalities with trientine treatment."
05/01/2015 - "To prospectively evaluate once-daily trientine as therapy for Wilson disease. "
06/01/2010 - "The selective Cu(II)-chelator, triethylenetetramine (TETA), is undergoing clinical trials for the treatment of heart failure in patients with diabetes. "
01/01/2013 - "However, direct in vivo evidence that trientine can improve cardiac function in heart failure has hitherto been lacking. "
01/01/2012 - "Based on evidence from the studies reviewed herein, trientine is now proceeding into the later stages of pharmaceutical development for the treatment of heart failure and other diabetic complications."
02/01/2007 - "Triethylenetetramine (TETA), a selective Cu(II)-chelator used in the treatment of Wilson's disease, is now undergoing clinical trials for the treatment of heart failure in diabetes. "
05/01/2005 - "We recently showed that treatment with the Cu(II)-selective chelator, trientine, alleviates heart failure in diabetic rats, improves left ventricular hypertrophy in humans with type 2 diabetes, and increases urinary Cu excretion in both diabetic rats and humans compared with nondiabetic control subjects. "
01/01/2013 - "Treatment with trientine, a divalent-copper-selective chelator, improves arterial and renal structure/function in diabetes, wherein it also ameliorates left-ventricular (LV) hypertrophy. "
05/01/2015 - "A number of recent studies report that the copper-specific orally-active chelator trientine can reduce risk for range of diabetic complications in rodents; a clinical trial with this agent demonstrated some decrease in left ventricular mass in diabetics with ventricular hypertrophy. "
|5.||Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
02/01/2003 - "The efficacy of trientine or ascorbate alone compared to that of the combined treatment with these two agents in familial amyotrophic lateral sclerosis model mice."
04/23/1999 - "Benefit of a combined treatment with trientine and ascorbate in familial amyotrophic lateral sclerosis model mice."
|4.||tetrathiomolybdate (ammonium tetrathiomolybdate)
|6.||Citric Acid (Citrate)
|10.||Blood Glucose (Blood Sugar)
|1.||Chelation Therapy (Therapy, Chelation)
|3.||Heterologous Transplantation (Xenotransplantation)
|4.||Transplantation (Transplant Recipients)
|5.||Drug Therapy (Chemotherapy)